How well does Epclusa(Sofosbuvir and Velpatasvir Tablets‌) work?

Summary of clinical trial outcomes demonstrating the drug's effectiveness.

Treatment Efficacy

Clinical trials demonstrated high efficacy for EPCLUSA across various patient groups. In adults without cirrhosis or with compensated cirrhosis, sustained virologic response rates were 95% to 100% across HCV genotypes 1, 2, 4, 5, and 6 after 12 weeks of treatment. For genotype 3, the rate was 95%. In patients with decompensated cirrhosis receiving EPCLUSA with ribavirin for 12 weeks, the overall SVR rate was 94%. High cure rates were also observed in pediatric patients, HIV-1 co-infected individuals, and liver transplant recipients.